Development of an advanced formula for the existing botulinum toxin product, and a next-generation botulinum toxin with new indications• Hyaluronic Acid Filler
Development of multi-functional fillers to maximize the effects of hyaluronic acid fillers currently available in the market• Transdermal Delivery System
Development of micro-needle and transcellular permeability carrier system for effective delivery of medication through the skin• Botulinum Toxin
Clinical testing for the treatment of blepharospasm, glabellar lines, pediatric cerebral palsy, and post stroke upper limb spasticity
HUGEL will conduct R&D to get diverse indications approved for botulinum toxin and will also apply advanced technology to seek methods to maximize effects of neurotoxin treatment.• Prevention and Treatment of Curable Hypertrophic Scars
Development of new pharmaceuticals using RNAi (RNA interference) molecules. Currently preclinical trials are underway and with successful development, HUGEL will be the first company in Korea to launch an RNAi pharmaceutical.